JBIO
Jade Biosciences, Inc.
$21.86
+0.52
(+2.44%)
Mkt Cap
713.20M
Volume
803,949
52W Range
6.67-28
Sector
Healthcare
Beta
1.43
EPS (TTM)
-2.92
P/E Ratio
-3.80
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (127.41M) | (69.63M) | (75.52M) | (51.51M) | (22.96M) | (9.61M) |
| EPS | -4.06 | -85.26 | -100.38 | -73.67 | -32.96 | -14.00 |
| Free Cash Flow | (94.89M) | (71.20M) | (56.92M) | (39.32M) | (27.58M) | (7.86M) |
| FCF / Share | -3.03 | -87.18 | -75.66 | -56.23 | -39.54 | -11.27 |
| Operating CF | (94.69M) | (71.20M) | (56.78M) | (39.12M) | (27.40M) | (7.86M) |
| Total Assets | 349.78M | 80.33M | 127.42M | 135.30M | 175.36M | 4.71M |
| Total Debt | 724,000 | 417,000 | 675,000 | 1.09M | 574,000 | 0 |
| Cash & Equiv | 88.44M | 33.75M | 23.49M | 22.40M | 54.20M | 4.57M |
| Book Value | 332.52M | 76.43M | 109.46M | 126.74M | 172.42M | 2.94M |
| Return on Equity | -0.38 | -0.91 | -0.69 | -0.41 | -0.13 | -3.27 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (40.37M) | (31.93M) | (25.18M) | (32.13M) | (2.52M) | (5.43M) | (16.28M) | (24.77M) | (23.19M) | (20.41M) | (19.56M) |
| EPS | -0.70 | -0.45 | -0.64 | -1.13 | -3.04 | -6.56 | -5.16 | -30.15 | -29.20 | -25.80 | -24.77 |
| Free Cash Flow | (24.08M) | (33.65M) | (22.18M) | (36.67M) | N/A | (11.05M) | 37.30M | (20.43M) | (23.67M) | (14.86M) | (15.64M) |
| FCF / Share | -0.42 | -0.48 | -0.56 | -1.29 | N/A | -13.34 | 11.82 | -24.87 | -29.81 | -18.78 | -19.81 |
| Operating CF | (24.08M) | (33.65M) | (22.12M) | (36.53M) | N/A | (11.05M) | 37.30M | (20.43M) | (23.67M) | (14.80M) | (15.61M) |
| Total Assets | 319.43M | 349.78M | 202.45M | 223.97M | 77.53M | 80.33M | 90.96M | 111.69M | 106.82M | 127.42M | 140.88M |
| Total Debt | 679,000 | 724,000 | 747,000 | 792,000 | 312,000 | 417,000 | 540,000 | 681,000 | 774,000 | 675,000 | 809,000 |
| Cash & Equiv | 55.09M | 88.44M | 50.11M | 220.94M | 44.22M | 33.75M | 31.11M | 31.07M | 9.12M | 23.49M | 32.18M |
| Book Value | 296.46M | 332.52M | 179.35M | 201.56M | 75.05M | 76.43M | 80.49M | 94.40M | 90.90M | 109.46M | 125.72M |
| Return on Equity | -0.14 | -0.10 | -0.14 | -0.16 | -0.03 | -0.07 | -0.20 | -0.26 | -0.26 | -0.19 | -0.16 |
JBIO News
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Jade Biosciences Announces Pricing of Public Offering of Common Stock
Jade Biosciences Announces Pricing of Public Offering of Common Stock
Jade Biosciences Announces Proposed Underwritten Public Offering
Jade Biosciences' JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials
Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans Transcript
Why Is Jade Biosciences Stock Trading Lower On Monday?
Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy